Therapeutic Potential of Bacteroides fragilis SNBF-1 as a Next-Generation Probiotic: In Vitro Efficacy in Lipid and Carbohydrate Metabolism and Antioxidant Activity

• Published in: Foods 2024-02, Vol.13 (5), p.735
• Main Authors: Cang, Weihe, Li, Xuan, Tang, Jiayi, Wang, Ying, Mu, Delun, Wu, Chunting, Shi, Haisu, Shi, Lin, Wu, Junrui, Wu, Rina
• Format: Article
• Language: English
• Subjects: Acids; Adaptability; Antibiotics; Antioxidants; B. fragilis; Bacteroides fragilis; Bile; Carbohydrate metabolism; Carbohydrates; Cell proliferation; Cholesterol; Energy metabolism; Feces; Genomes; Genotypes; Glucosidase; Glycogen; Glycogens; Inflammatory bowel disease; Insulin; Intestinal microflora; Lipid metabolism; Lipids; Metabolism; Microbiomes; Microbiota; next-generation probiotics; Phenotypes; probiotic function; Probiotics; Salt; Scavenging; Strains (organisms); Therapeutic applications; toxicity; α-Amylase; α-Glucosidase
• ISSN: 2304-8158; 2304-8158
• DOI: 10.3390/foods13050735

This study explores the potential of aerotolerant Bacteroides fragilis ( ) strains as next-generation probiotics (NGPs), focusing on their adaptability in the gastrointestinal environment, safety profile, and probiotic functions. From 23 healthy infant fecal samples, we successfully isolated 56 beneficial strains. Notably, the SNBF-1 strain demonstrated superior cholesterol removal efficiency in HepG2 cells, outshining all other strains by achieving a remarkable reduction in cholesterol by 55.38 ± 2.26%. Comprehensive genotype and phenotype analyses were conducted, including sugar utilization and antibiotic sensitivity tests, leading to the development of an optimized growth medium for SNBF-1. SNBF-1 also demonstrated robust and consistent antioxidant activity, particularly in cell-free extracts, as evidenced by an average oxygen radical absorbance capacity value of 1.061 and a 2,2-diphenyl-1-picrylhydrazyl scavenging ability of 94.53 ± 7.31%. The regulation of carbohydrate metabolism by SNBF-1 was assessed in the insulin-resistant HepG2 cell line. In enzyme inhibition assays, SNBF-1 showed significant α-amylase and α-glucosidase inhibition, with rates of 87.04 ± 2.03% and 37.82 ± 1.36%, respectively. Furthermore, the cell-free supernatant (CFS) of SNBF-1 enhanced glucose consumption and glycogen synthesis in insulin-resistant HepG2 cells, indicating improved cellular energy metabolism. This was consistent with the observation that the CFS of SNBF-1 increased the proliferation of HepG2 cells by 123.77 ± 0.82% compared to that of the control. Overall, this research significantly enhances our understanding of NGPs and their potential therapeutic applications in modulating the gut microbiome.